Buprenorphine therapy in the setting of induced opioid withdrawal from oral naltrexone: a case report Article Swipe
Laura M. Szczesniak
,
Vincent Calleo
,
Ross Sullivan
·
YOU?
·
· 2020
· Open Access
·
· DOI: https://doi.org/10.1186/s12954-020-00417-9
YOU?
·
· 2020
· Open Access
·
· DOI: https://doi.org/10.1186/s12954-020-00417-9
Background Patients with opioid use disorder (OUD) frequently present to the emergency department for acute treatment of overdose and withdrawal. Case presentation A 29-year-old male presented to the emergency room after intravenous heroin use followed by accidental ingestion of naltrexone. He was treated with buprenorphine with significant improvement in his Clinical Opioid Withdrawal Score, from moderately severe to mild withdrawal symptoms within a few hours. Conclusion Buprenorphine and minimal supportive care can be used to treat acute withdrawal precipitated by oral naltrexone in patients with OUD.
Related Topics
Concepts
Naltrexone
Buprenorphine
Medicine
Heroin
Opioid use disorder
Opioid
Anesthesia
(+)-Naloxone
Emergency department
Opioid overdose
Psychiatry
Internal medicine
Drug
Receptor
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1186/s12954-020-00417-9
- https://harmreductionjournal.biomedcentral.com/track/pdf/10.1186/s12954-020-00417-9
- OA Status
- gold
- Cited By
- 4
- References
- 8
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W3092229787
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W3092229787Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1186/s12954-020-00417-9Digital Object Identifier
- Title
-
Buprenorphine therapy in the setting of induced opioid withdrawal from oral naltrexone: a case reportWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2020Year of publication
- Publication date
-
2020-10-07Full publication date if available
- Authors
-
Laura M. Szczesniak, Vincent Calleo, Ross SullivanList of authors in order
- Landing page
-
https://doi.org/10.1186/s12954-020-00417-9Publisher landing page
- PDF URL
-
https://harmreductionjournal.biomedcentral.com/track/pdf/10.1186/s12954-020-00417-9Direct link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://harmreductionjournal.biomedcentral.com/track/pdf/10.1186/s12954-020-00417-9Direct OA link when available
- Concepts
-
Naltrexone, Buprenorphine, Medicine, Heroin, Opioid use disorder, Opioid, Anesthesia, (+)-Naloxone, Emergency department, Opioid overdose, Psychiatry, Internal medicine, Drug, ReceptorTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
4Total citation count in OpenAlex
- Citations by year (recent)
-
2024: 1, 2021: 2, 2020: 1Per-year citation counts (last 5 years)
- References (count)
-
8Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W3092229787 |
|---|---|
| doi | https://doi.org/10.1186/s12954-020-00417-9 |
| ids.doi | https://doi.org/10.1186/s12954-020-00417-9 |
| ids.mag | 3092229787 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/33028340 |
| ids.openalex | https://openalex.org/W3092229787 |
| fwci | 0.64103164 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D000328 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Adult |
| mesh[1].qualifier_ui | Q000627 |
| mesh[1].descriptor_ui | D000701 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | therapeutic use |
| mesh[1].descriptor_name | Analgesics, Opioid |
| mesh[2].qualifier_ui | Q000627 |
| mesh[2].descriptor_ui | D002047 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | therapeutic use |
| mesh[2].descriptor_name | Buprenorphine |
| mesh[3].qualifier_ui | |
| mesh[3].descriptor_ui | D006801 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | |
| mesh[3].descriptor_name | Humans |
| mesh[4].qualifier_ui | |
| mesh[4].descriptor_ui | D008297 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | |
| mesh[4].descriptor_name | Male |
| mesh[5].qualifier_ui | Q000008 |
| mesh[5].descriptor_ui | D009271 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | administration & dosage |
| mesh[5].descriptor_name | Naltrexone |
| mesh[6].qualifier_ui | Q000009 |
| mesh[6].descriptor_ui | D009271 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | adverse effects |
| mesh[6].descriptor_name | Naltrexone |
| mesh[7].qualifier_ui | Q000627 |
| mesh[7].descriptor_ui | D009292 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | therapeutic use |
| mesh[7].descriptor_name | Narcotic Antagonists |
| mesh[8].qualifier_ui | Q000150 |
| mesh[8].descriptor_ui | D009293 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | complications |
| mesh[8].descriptor_name | Opioid-Related Disorders |
| mesh[9].qualifier_ui | Q000188 |
| mesh[9].descriptor_ui | D009293 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | drug therapy |
| mesh[9].descriptor_name | Opioid-Related Disorders |
| mesh[10].qualifier_ui | Q000188 |
| mesh[10].descriptor_ui | D013375 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | drug therapy |
| mesh[10].descriptor_name | Substance Withdrawal Syndrome |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D016896 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Treatment Outcome |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D000328 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Adult |
| mesh[13].qualifier_ui | Q000627 |
| mesh[13].descriptor_ui | D000701 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | therapeutic use |
| mesh[13].descriptor_name | Analgesics, Opioid |
| mesh[14].qualifier_ui | Q000627 |
| mesh[14].descriptor_ui | D002047 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | therapeutic use |
| mesh[14].descriptor_name | Buprenorphine |
| mesh[15].qualifier_ui | |
| mesh[15].descriptor_ui | D006801 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | |
| mesh[15].descriptor_name | Humans |
| mesh[16].qualifier_ui | |
| mesh[16].descriptor_ui | D008297 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | |
| mesh[16].descriptor_name | Male |
| mesh[17].qualifier_ui | Q000008 |
| mesh[17].descriptor_ui | D009271 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | administration & dosage |
| mesh[17].descriptor_name | Naltrexone |
| mesh[18].qualifier_ui | Q000009 |
| mesh[18].descriptor_ui | D009271 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | adverse effects |
| mesh[18].descriptor_name | Naltrexone |
| mesh[19].qualifier_ui | Q000627 |
| mesh[19].descriptor_ui | D009292 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | therapeutic use |
| mesh[19].descriptor_name | Narcotic Antagonists |
| mesh[20].qualifier_ui | Q000150 |
| mesh[20].descriptor_ui | D009293 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | complications |
| mesh[20].descriptor_name | Opioid-Related Disorders |
| mesh[21].qualifier_ui | Q000188 |
| mesh[21].descriptor_ui | D009293 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | drug therapy |
| mesh[21].descriptor_name | Opioid-Related Disorders |
| mesh[22].qualifier_ui | Q000188 |
| mesh[22].descriptor_ui | D013375 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | drug therapy |
| mesh[22].descriptor_name | Substance Withdrawal Syndrome |
| mesh[23].qualifier_ui | |
| mesh[23].descriptor_ui | D016896 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | |
| mesh[23].descriptor_name | Treatment Outcome |
| type | article |
| title | Buprenorphine therapy in the setting of induced opioid withdrawal from oral naltrexone: a case report |
| biblio.issue | 1 |
| biblio.volume | 17 |
| biblio.last_page | 71 |
| biblio.first_page | 71 |
| topics[0].id | https://openalex.org/T10576 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2739 |
| topics[0].subfield.display_name | Public Health, Environmental and Occupational Health |
| topics[0].display_name | Opioid Use Disorder Treatment |
| topics[1].id | https://openalex.org/T11199 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.996999979019165 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2703 |
| topics[1].subfield.display_name | Anesthesiology and Pain Medicine |
| topics[1].display_name | Pain Management and Opioid Use |
| topics[2].id | https://openalex.org/T11635 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9965000152587891 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2711 |
| topics[2].subfield.display_name | Emergency Medicine |
| topics[2].display_name | Poisoning and overdose treatments |
| is_xpac | False |
| apc_list.value | 1990 |
| apc_list.currency | GBP |
| apc_list.value_usd | 2440 |
| apc_paid.value | 1990 |
| apc_paid.currency | GBP |
| apc_paid.value_usd | 2440 |
| concepts[0].id | https://openalex.org/C2777972943 |
| concepts[0].level | 4 |
| concepts[0].score | 0.9264517426490784 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q409587 |
| concepts[0].display_name | Naltrexone |
| concepts[1].id | https://openalex.org/C2778949969 |
| concepts[1].level | 4 |
| concepts[1].score | 0.8949547410011292 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q407721 |
| concepts[1].display_name | Buprenorphine |
| concepts[2].id | https://openalex.org/C71924100 |
| concepts[2].level | 0 |
| concepts[2].score | 0.7815035581588745 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[2].display_name | Medicine |
| concepts[3].id | https://openalex.org/C2778903686 |
| concepts[3].level | 3 |
| concepts[3].score | 0.6988816261291504 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q60168 |
| concepts[3].display_name | Heroin |
| concepts[4].id | https://openalex.org/C2779418921 |
| concepts[4].level | 4 |
| concepts[4].score | 0.6236340999603271 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q1639178 |
| concepts[4].display_name | Opioid use disorder |
| concepts[5].id | https://openalex.org/C2781063702 |
| concepts[5].level | 3 |
| concepts[5].score | 0.5111051201820374 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q427523 |
| concepts[5].display_name | Opioid |
| concepts[6].id | https://openalex.org/C42219234 |
| concepts[6].level | 1 |
| concepts[6].score | 0.4983060359954834 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q131130 |
| concepts[6].display_name | Anesthesia |
| concepts[7].id | https://openalex.org/C2778750930 |
| concepts[7].level | 4 |
| concepts[7].score | 0.46102768182754517 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q4540629 |
| concepts[7].display_name | (+)-Naloxone |
| concepts[8].id | https://openalex.org/C2780724011 |
| concepts[8].level | 2 |
| concepts[8].score | 0.4395403563976288 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q1295316 |
| concepts[8].display_name | Emergency department |
| concepts[9].id | https://openalex.org/C2779148768 |
| concepts[9].level | 5 |
| concepts[9].score | 0.4117482602596283 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q17154378 |
| concepts[9].display_name | Opioid overdose |
| concepts[10].id | https://openalex.org/C118552586 |
| concepts[10].level | 1 |
| concepts[10].score | 0.24671849608421326 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q7867 |
| concepts[10].display_name | Psychiatry |
| concepts[11].id | https://openalex.org/C126322002 |
| concepts[11].level | 1 |
| concepts[11].score | 0.15424096584320068 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[11].display_name | Internal medicine |
| concepts[12].id | https://openalex.org/C2780035454 |
| concepts[12].level | 2 |
| concepts[12].score | 0.13401460647583008 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q8386 |
| concepts[12].display_name | Drug |
| concepts[13].id | https://openalex.org/C170493617 |
| concepts[13].level | 2 |
| concepts[13].score | 0.0 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q208467 |
| concepts[13].display_name | Receptor |
| keywords[0].id | https://openalex.org/keywords/naltrexone |
| keywords[0].score | 0.9264517426490784 |
| keywords[0].display_name | Naltrexone |
| keywords[1].id | https://openalex.org/keywords/buprenorphine |
| keywords[1].score | 0.8949547410011292 |
| keywords[1].display_name | Buprenorphine |
| keywords[2].id | https://openalex.org/keywords/medicine |
| keywords[2].score | 0.7815035581588745 |
| keywords[2].display_name | Medicine |
| keywords[3].id | https://openalex.org/keywords/heroin |
| keywords[3].score | 0.6988816261291504 |
| keywords[3].display_name | Heroin |
| keywords[4].id | https://openalex.org/keywords/opioid-use-disorder |
| keywords[4].score | 0.6236340999603271 |
| keywords[4].display_name | Opioid use disorder |
| keywords[5].id | https://openalex.org/keywords/opioid |
| keywords[5].score | 0.5111051201820374 |
| keywords[5].display_name | Opioid |
| keywords[6].id | https://openalex.org/keywords/anesthesia |
| keywords[6].score | 0.4983060359954834 |
| keywords[6].display_name | Anesthesia |
| keywords[7].id | https://openalex.org/keywords/naloxone |
| keywords[7].score | 0.46102768182754517 |
| keywords[7].display_name | (+)-Naloxone |
| keywords[8].id | https://openalex.org/keywords/emergency-department |
| keywords[8].score | 0.4395403563976288 |
| keywords[8].display_name | Emergency department |
| keywords[9].id | https://openalex.org/keywords/opioid-overdose |
| keywords[9].score | 0.4117482602596283 |
| keywords[9].display_name | Opioid overdose |
| keywords[10].id | https://openalex.org/keywords/psychiatry |
| keywords[10].score | 0.24671849608421326 |
| keywords[10].display_name | Psychiatry |
| keywords[11].id | https://openalex.org/keywords/internal-medicine |
| keywords[11].score | 0.15424096584320068 |
| keywords[11].display_name | Internal medicine |
| keywords[12].id | https://openalex.org/keywords/drug |
| keywords[12].score | 0.13401460647583008 |
| keywords[12].display_name | Drug |
| language | en |
| locations[0].id | doi:10.1186/s12954-020-00417-9 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S150411170 |
| locations[0].source.issn | 1477-7517 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 1477-7517 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Harm Reduction Journal |
| locations[0].source.host_organization | https://openalex.org/P4310320256 |
| locations[0].source.host_organization_name | BioMed Central |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320256, https://openalex.org/P4310319965 |
| locations[0].source.host_organization_lineage_names | BioMed Central, Springer Nature |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://harmreductionjournal.biomedcentral.com/track/pdf/10.1186/s12954-020-00417-9 |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Harm Reduction Journal |
| locations[0].landing_page_url | https://doi.org/10.1186/s12954-020-00417-9 |
| locations[1].id | pmid:33028340 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Harm reduction journal |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/33028340 |
| locations[2].id | pmh:oai:doaj.org/article:ef85a6b6d75b4526b1e526651cd4e3be |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S4306401280 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[2].source.host_organization | |
| locations[2].source.host_organization_name | |
| locations[2].license | cc-by-sa |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | article |
| locations[2].license_id | https://openalex.org/licenses/cc-by-sa |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Harm Reduction Journal, Vol 17, Iss 1, Pp 1-3 (2020) |
| locations[2].landing_page_url | https://doaj.org/article/ef85a6b6d75b4526b1e526651cd4e3be |
| locations[3].id | pmh:oai:pubmedcentral.nih.gov:7542394 |
| locations[3].is_oa | True |
| locations[3].source.id | https://openalex.org/S2764455111 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | PubMed Central |
| locations[3].source.host_organization | https://openalex.org/I1299303238 |
| locations[3].source.host_organization_name | National Institutes of Health |
| locations[3].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[3].license | other-oa |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | Text |
| locations[3].license_id | https://openalex.org/licenses/other-oa |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | Harm Reduct J |
| locations[3].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/7542394 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5016872927 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-5321-9821 |
| authorships[0].author.display_name | Laura M. Szczesniak |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I20388574 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Pharmacology, Upstate Medical University, 750 E Adams St, Syracuse, NY, 13210, USA |
| authorships[0].institutions[0].id | https://openalex.org/I20388574 |
| authorships[0].institutions[0].ror | https://ror.org/040kfrw16 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I20388574 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | SUNY Upstate Medical University |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Laura M. Szczesniak |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Department of Pharmacology, Upstate Medical University, 750 E Adams St, Syracuse, NY, 13210, USA |
| authorships[1].author.id | https://openalex.org/A5061202253 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Vincent Calleo |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I20388574 |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Emergency Medicine, Upstate Medical University, 750 E Adams St, Syracuse, NY, 13210, USA |
| authorships[1].institutions[0].id | https://openalex.org/I20388574 |
| authorships[1].institutions[0].ror | https://ror.org/040kfrw16 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I20388574 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | SUNY Upstate Medical University |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Vincent J. Calleo |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Department of Emergency Medicine, Upstate Medical University, 750 E Adams St, Syracuse, NY, 13210, USA |
| authorships[2].author.id | https://openalex.org/A5020869289 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Ross Sullivan |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I20388574 |
| authorships[2].affiliations[0].raw_affiliation_string | Department of Emergency Medicine, Upstate Medical University, 750 E Adams St, Syracuse, NY, 13210, USA |
| authorships[2].institutions[0].id | https://openalex.org/I20388574 |
| authorships[2].institutions[0].ror | https://ror.org/040kfrw16 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I20388574 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | SUNY Upstate Medical University |
| authorships[2].author_position | last |
| authorships[2].raw_author_name | Ross W. Sullivan |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Department of Emergency Medicine, Upstate Medical University, 750 E Adams St, Syracuse, NY, 13210, USA |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://harmreductionjournal.biomedcentral.com/track/pdf/10.1186/s12954-020-00417-9 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Buprenorphine therapy in the setting of induced opioid withdrawal from oral naltrexone: a case report |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10576 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2739 |
| primary_topic.subfield.display_name | Public Health, Environmental and Occupational Health |
| primary_topic.display_name | Opioid Use Disorder Treatment |
| related_works | https://openalex.org/W3183150022, https://openalex.org/W4211068096, https://openalex.org/W3082216162, https://openalex.org/W4283446732, https://openalex.org/W1967577351, https://openalex.org/W4385737324, https://openalex.org/W2898142040, https://openalex.org/W4317734534, https://openalex.org/W4318670906, https://openalex.org/W3153408657 |
| cited_by_count | 4 |
| counts_by_year[0].year | 2024 |
| counts_by_year[0].cited_by_count | 1 |
| counts_by_year[1].year | 2021 |
| counts_by_year[1].cited_by_count | 2 |
| counts_by_year[2].year | 2020 |
| counts_by_year[2].cited_by_count | 1 |
| locations_count | 4 |
| best_oa_location.id | doi:10.1186/s12954-020-00417-9 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S150411170 |
| best_oa_location.source.issn | 1477-7517 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 1477-7517 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Harm Reduction Journal |
| best_oa_location.source.host_organization | https://openalex.org/P4310320256 |
| best_oa_location.source.host_organization_name | BioMed Central |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320256, https://openalex.org/P4310319965 |
| best_oa_location.source.host_organization_lineage_names | BioMed Central, Springer Nature |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://harmreductionjournal.biomedcentral.com/track/pdf/10.1186/s12954-020-00417-9 |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Harm Reduction Journal |
| best_oa_location.landing_page_url | https://doi.org/10.1186/s12954-020-00417-9 |
| primary_location.id | doi:10.1186/s12954-020-00417-9 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S150411170 |
| primary_location.source.issn | 1477-7517 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 1477-7517 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Harm Reduction Journal |
| primary_location.source.host_organization | https://openalex.org/P4310320256 |
| primary_location.source.host_organization_name | BioMed Central |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320256, https://openalex.org/P4310319965 |
| primary_location.source.host_organization_lineage_names | BioMed Central, Springer Nature |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://harmreductionjournal.biomedcentral.com/track/pdf/10.1186/s12954-020-00417-9 |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Harm Reduction Journal |
| primary_location.landing_page_url | https://doi.org/10.1186/s12954-020-00417-9 |
| publication_date | 2020-10-07 |
| publication_year | 2020 |
| referenced_works | https://openalex.org/W3012261821, https://openalex.org/W2987196569, https://openalex.org/W2947222671, https://openalex.org/W2911825378, https://openalex.org/W2906757530, https://openalex.org/W2018914766, https://openalex.org/W2079048853, https://openalex.org/W2923138552 |
| referenced_works_count | 8 |
| abstract_inverted_index.A | 23 |
| abstract_inverted_index.a | 63 |
| abstract_inverted_index.He | 41 |
| abstract_inverted_index.be | 73 |
| abstract_inverted_index.by | 36, 80 |
| abstract_inverted_index.in | 49, 83 |
| abstract_inverted_index.of | 17, 39 |
| abstract_inverted_index.to | 10, 27, 58, 75 |
| abstract_inverted_index.and | 19, 68 |
| abstract_inverted_index.can | 72 |
| abstract_inverted_index.few | 64 |
| abstract_inverted_index.for | 14 |
| abstract_inverted_index.his | 50 |
| abstract_inverted_index.the | 11, 28 |
| abstract_inverted_index.use | 5, 34 |
| abstract_inverted_index.was | 42 |
| abstract_inverted_index.Case | 21 |
| abstract_inverted_index.OUD. | 86 |
| abstract_inverted_index.care | 71 |
| abstract_inverted_index.from | 55 |
| abstract_inverted_index.male | 25 |
| abstract_inverted_index.mild | 59 |
| abstract_inverted_index.oral | 81 |
| abstract_inverted_index.room | 30 |
| abstract_inverted_index.used | 74 |
| abstract_inverted_index.with | 3, 44, 46, 85 |
| abstract_inverted_index.(OUD) | 7 |
| abstract_inverted_index.acute | 15, 77 |
| abstract_inverted_index.after | 31 |
| abstract_inverted_index.treat | 76 |
| abstract_inverted_index.Opioid | 52 |
| abstract_inverted_index.Score, | 54 |
| abstract_inverted_index.heroin | 33 |
| abstract_inverted_index.hours. | 65 |
| abstract_inverted_index.opioid | 4 |
| abstract_inverted_index.severe | 57 |
| abstract_inverted_index.within | 62 |
| abstract_inverted_index.minimal | 69 |
| abstract_inverted_index.present | 9 |
| abstract_inverted_index.treated | 43 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.Clinical | 51 |
| abstract_inverted_index.Patients | 2 |
| abstract_inverted_index.disorder | 6 |
| abstract_inverted_index.followed | 35 |
| abstract_inverted_index.overdose | 18 |
| abstract_inverted_index.patients | 84 |
| abstract_inverted_index.symptoms | 61 |
| abstract_inverted_index.emergency | 12, 29 |
| abstract_inverted_index.ingestion | 38 |
| abstract_inverted_index.presented | 26 |
| abstract_inverted_index.treatment | 16 |
| abstract_inverted_index.Background | 1 |
| abstract_inverted_index.Conclusion | 66 |
| abstract_inverted_index.Withdrawal | 53 |
| abstract_inverted_index.accidental | 37 |
| abstract_inverted_index.department | 13 |
| abstract_inverted_index.frequently | 8 |
| abstract_inverted_index.moderately | 56 |
| abstract_inverted_index.naltrexone | 82 |
| abstract_inverted_index.supportive | 70 |
| abstract_inverted_index.withdrawal | 60, 78 |
| abstract_inverted_index.29-year-old | 24 |
| abstract_inverted_index.improvement | 48 |
| abstract_inverted_index.intravenous | 32 |
| abstract_inverted_index.naltrexone. | 40 |
| abstract_inverted_index.significant | 47 |
| abstract_inverted_index.withdrawal. | 20 |
| abstract_inverted_index.precipitated | 79 |
| abstract_inverted_index.presentation | 22 |
| abstract_inverted_index.Buprenorphine | 67 |
| abstract_inverted_index.buprenorphine | 45 |
| cited_by_percentile_year.max | 95 |
| cited_by_percentile_year.min | 89 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 3 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8799999952316284 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.71927773 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |